[1]叶子鸣,许 敏,王黎洲,等.梗阻性黄疸PTCD出血并发症的危险因素[J].介入放射学杂志,2024,33(05):500-506.
 YE Ziming,XU Min,WANG Lizhou,et al.Risk factors of bleeding complications in patients with obstructive jaundice after percutaneous transhepatic cholangial drainage[J].journal interventional radiology,2024,33(05):500-506.
点击复制

梗阻性黄疸PTCD出血并发症的危险因素()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
33
期数:
2024年05
页码:
500-506
栏目:
非血管介入
出版日期:
2024-06-03

文章信息/Info

Title:
Risk factors of bleeding complications in patients with obstructive jaundice after percutaneous transhepatic cholangial drainage
作者:
叶子鸣 许 敏 王黎洲 周 石 李 兴
Author(s):
YE Ziming XU Min WANG Lizhou ZHOU Shi LI Xing.
Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou Province 550004, China
关键词:
【关键词】 经皮肝穿刺胆道置管引流术 梗阻性黄疸 胆道出血 并发症 危险因素
文献标志码:
A
摘要:
【摘要】 目的 探讨梗阻性黄疸患者经皮肝穿刺胆道置管引流术(percutaneous transhepatic cholangial drainage,PTCD)出血并发症相关的影响因素。方法 收集贵州医科大学附属医院、中南大学湘雅二医院、贵州医科大学附属肿瘤医院2015年1月至2021年1月,接受PTCD资料完整的1 042例梗阻性黄疸患者的临床资料,并对PTCD出血并发症相关的危险因素进行回顾性分析。结果 引流管成襻位置对PTCD出血并发症有影响,差异有统计学意义(P<0.01),与总胆管成襻位置相比,左右肝管成襻术后出血风险增加155.6%(OR=2.556, 95%CI: 1.251~5.225),左右肝管下一级分支成襻术后出血增加414.4% (OR=5.144, 95% CI: 2.618~10.106)。穿刺成功后引流方式选择差异有统计学意义(P<0.05),与外引流方式相比,内外共同引流方式增加术后出血风险159.1%(OR=2.591,95% CI: 1.102~6.091)。术前血小板计数与术前总胆红素水平为PTCD出血并发症的独立危险因素(P<0.05);术前血小板计数每增加1个单位,术后出血并发症的发生的概率减少0.2%(OR=0.998, 95%CI: 0.995~1.000),且术前血小板计数<228×109/L时,对术后出血产生影响;术前总胆红素每增加1个单位,术后出血并发症的发生概率增加0.3%(OR=1.003, 95%CI: 1.001~1.004),且术前总胆红素>264.4 μmol/L时,对术后出血产生影响。结论 PTCD引流管成襻位置及引流方式是PTCD出血并发症的独立危险因素,成襻位置越靠近三级分支,出血风险越大;内外引流方式的出血风险高于外引流方式。术前总胆红素、术前血小板计数是PTCD出血并发症的独立危险因素;术前总胆红素水平与出血风险呈正相关;术前血小板计数水平与出血风险呈负相关。

参考文献/References:

[1] Navaneethan U, Jayanthi V, Mohan P. Pathogenesis of cholangitis in obstructive jaundice- revisited[J]. Minerva Gastroenterol Dietol, 2011, 57: 97- 104.
[2] Pavlidis ET,Pavlidis TE. Pathophysiological consequences of obstructive jaundice and perioperative management[J]. Hepato- biliary Pancreat Dis Int, 2018, 17: 17 21.
[3] Schreyer N, Allard D. “Damage control surgery”(DCS): just the surgery the patient needs[J]. Rev Med Suisse,2008,4:1754- 1756, 1758.
[4] Bao G, Liu H, Ma Y,et al. The clinical efficacy and safety of different biliary drainages in malignant obstructive jaundice treatment[J]. Am J Transl Res,2021,13:7400- 7405.
[5] Nennstiel S,Weber A,Frick G,et al. Drainage- related comp-lications in percutaneous transhepatic biliary drainage: an analysis over 10 years[J]. J Clin Gastroenterol, 2015, 49: 764- 770.
[6] Lynn PB, Warnack EM, Parikh M, et al. Hemobilia as a complication of transhepatic percutaneous biliary drainage: a rare indication for laparoscopic common bile duct exploration[J]. J Gastrointest Surg, 2020, 24: 2703.
[7] Quencer KB,Tadros AS,Marashi KB,et al. Bleeding after percutaneous transhepatic biliary drainage: incidence, causes and treatments[J]. J Clin Med, 2018, 7: 94.
[8] Choi SH, Gwon DI, Ko GY, et al. Hepatic arterial injuries in 3110 patients following percutaneous transhepatic biliary drainage[J]. Radiology, 2011, 261: 969- 975.
[9] Houghton EJ, Zeledon M, Acquafresca P, et al. Prospective comparison of bleeding complications between right and left approaches in percutaneous biliary drainage[J]. Surg Laparosc Endosc Percutan Tech, 2019, 29: 7- 12.
[10] Weber A, Gaa J, Rosca B, et al. Complications of percutaneous transhepatic biliary drainage in patients with dilated and nondilated intrahepatic bile ducts[J]. Eur J Radiol,2009 ,72:412- 417.
[11] Shimizu H, Itoi T, Sano K. Historical development of percutaneous transhepatic biliary interventions[J]. J Hepatobiliary Pancreat Sci, 2018, 25: 281- 282.
[12] Houghton EJ, Uribe AK, de Battista JM, et al. Risk factors for hemorrhagic adverse events in percutaneous transhepatic biliary drainage: a prospective multicenter study[J]. J Vasc Interv Radiol , 2022, 33: 919- 925.
[13] Fidelman N,Bloom AI,Kerlan RK Jr,et al. Hepatic arterial injuries after percutaneous biliary interventions in the era of laparoscopic surgery and liver transplantation: experience with 930 patients[J]. Radiology, 2008, 247: 880- 886.
[14] Aung TH,Too CW,Kumar N,et al. Severe bleeding after percu-taneous transhepatic drainage of the biliary system[J]. Radiology, 2016, 278: 957- 958.
[15] Modha K. Clinical approach to patients with obstructive jaundice[J]. Tech Vasc Interv Radiol, 2015, 18: 197- 200.
[16] Lee YT, Yen KC, Liang PC, et al. Procedure- related risk factors for bleeding after percutaneous transhepatic biliary drainage: a systematic review and meta- analysis[J]. J Formos Med Assoc, 2022, 121: 1680- 1688.
[17] Saad WE, Wallace MJ, Wojak JC, et al. Quality improvement guidelines for percutaneous transhepatic cholangiography, biliary drainage,and percutaneous cholecystostomy[J]. J Vasc Interv Radiol, 2010, 21: 789- 795.
[18] Pulappadi VP,Srivastava DN,Madhusudhan KS. Diagnosis and management of hemorrhagic complications of percutaneous trans- hepatic biliary drainage: a primer for residents[J]. Br J Radiol, 2021, 94: 20200879.
[19] 雷东酿,娄琳滟,江哲宇,等. 经皮肝穿刺胆道引流术前预防性使用抗生素对术后胆道感染的影响[J]. 介入放射学杂志, 2022, 31:879- 882.
[20] Duan F,Cui L,Bai Y,et al. Comparison of efficacy and compli- cations of endoscopic and percutaneous biliary drainage in malignant obstructive jaundice: a systematic review and meta- analysis[J]. Cancer Imaging, 2017, 17: 27.
[21] Morimoto M,Tomassini F,Berardi G,et al. Glissonean approach for hepatic inflow control in minimally invasive anatomic liver resection: a systematic review[J]. J Hepatobiliary Pancreat Sci, 2022, 29:51- 65.
[22] Duan F, Cui L, Bai YH, et al. Comparison of efficacy and complications of endoscopic and percutaneous biliary drainage in malignant obstructive jaundice: a systematic review and meta- analysis[J]. Cancer Imaging, 2017, 17: 27.
[23] Komaya K,Ebata T,Fukami Y,et al. Percutaneous biliary drainage is oncologically inferior to endoscopic drainage: a propensity score matching analysis in resectable distal cholangiocarcinoma[J]. J Gastroenterol, 2016, 51:608- 619.
[24] Matoori S,Froehlich JM,Breitenstein S,et al. Serum albumin, total bilirubin, and patient age are independent confounders of hepatobiliary- phase gadoxetate parenchymal liver enhancement[J]. Eur Radiol, 2019, 29: 5813- 5822.
[25] Queen T,Cox K,Adler DG. Primary sclerosing cholangitis in the setting of normal liver chemistries can be associated with severe ductal disease and dominant strictures[J]. Dig Dis Sci, 2014, 59: 229- 230.
[26] Slichter SJ,Kaufman RM,Assmann SF,et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage[J]. N Engl J Med, 2010, 362: 600- 613.
[27] Uhl L,Assmann SF,Hamza TH,et al. Laboratory predictors of bleeding and the effect of platelet and RBC transfusions on bleeding outcomes in the PLADO trial[J]. Blood, 2017, 130: 1247- 1258.
[28] Magder S. Diastolic pressure should be used to guide management of patients in shock: PRO[J]. J Crit Care, 2019, 51: 241- 243.
[29] 范本芳,杨海霞,何伯圣,等. PBL结合微视频健康教育方案在PTCD带管患者中的应用[J]. 介入放射学杂志, 2020, 29:621- 625.
[30] Gupta P, Maralakunte M, Rathee S, et al. Percutaneous transhepatic biliary drainage in patients at higher risk for adverse events: experience from a tertiary care referral center[J]. Abdom Radiol(NY), 2020, 45: 2547- 2553.
[31] Shiau EL,Liang HL,Lin YH,et al. The complication of hepatic artery injuries of 1,304 percutaneous transhepatic biliary drainage in a single institute[J]. J Vasc Interv Radiol, 2017, 28: 1025- 1032.
[32] Mayhew D, Mendonca V, Murthy BVS. A review of ASA physical status- historical perspectives and modern developments[J]. Anaesthesia, 2019, 74: 373- 379.

相似文献/References:

[1]尹卫民,周建新,谢敏,等.经皮肝穿植入胆道内支架治疗胆道狭窄[J].介入放射学杂志,1995,(04):192.
[2]王小林.胆道支架的进展与开发[J].介入放射学杂志,1998,(03):129.
[3]杨顺春,顾海燕,徐骁,等.经皮肝穿刺胆道造影在老年梗阻性黄疸病因诊断中的应用[J].介入放射学杂志,2000,(02):93.
[4]牛洪涛,翟仁友,王剑锋,等.胃癌合并梗阻性黄疸经皮经肝胆道引流术后中、长期疗效分析[J].介入放射学杂志,2011,(03):227.
 NIU Hong-tao,ZHAI Ren-you,WANG Jian-feng,et al.PTBD for the treatment of malignant obstructive jaundice associated with gastric cancer: an analysis of middle-term and long-term efficacy[J].journal interventional radiology,2011,(05):227.
[5]程 龙,靳 勇,白旭明,等. 经皮经肝胆道引流术后胆道感染的相关因素分析[J].介入放射学杂志,2012,(06):509.
 CHENG Long,JIN Yong,BAI Xu- ming,et al. Biliary infection occurred after percutaneous transhepatic biliary drainage: an analysis of the related factors[J].journal interventional radiology,2012,(05):509.
[6]赵晓阳,曹会存,李天晓,等. 经皮肝穿胆道引流术联合125I粒子植入治疗晚期胰腺癌合并梗阻性黄疸[J].介入放射学杂志,2013,(08):650.
 ZHAO Xiao? yang,CAO Hui? cun,LI Tian? xiao,et al. PTCD combined with 125I seed implantation for the treatment of advanced pancreatic cancer associated with obstructive jaundice[J].journal interventional radiology,2013,(05):650.
[7]金 壮,曹军英,张 筠,等.超声引导下PTCD与ERCP联合治疗恶性梗阻性黄疸十例[J].介入放射学杂志,2015,(03):223.
 JIN Zhuang,CAO Jun ying,ZHANG Yun,et al.Ultrasound guided PTCD combined with ERCP for the treatment of malignant obstructive jaundice: initial experience in 10 cases[J].journal interventional radiology,2015,(05):223.
[8]任建庄,张 凯,李腾飞,等.中下段胆总管癌致恶性梗阻性黄疸介入治疗疗效分析[J].介入放射学杂志,2015,(05):409.
 REN Jian zhuang,ZHANG Kai,LI Teng fei,et al.Interventional therapy for malignant obstructive jaundice caused by cholangiocarcinoma located at middle low segment of common bile duct: analysis of curative effect[J].journal interventional radiology,2015,(05):409.
[9]施东华,翟 博,沈加林.经皮胆道支架联合近距内放疗治疗不能手术切除的肝门胆管癌 [J].介入放射学杂志,2017,(03):243.
 SHI Donghua,ZHAI Bo,SHEN Jialin.Percutaneous biliary stenting combined with brachytherapy for the treatment of unresectable Klatskin’s tumor[J].journal interventional radiology,2017,(05):243.
[10]张金星,祖庆泉,施海彬.金属支架治疗胰腺癌合并梗阻性黄疸42例预后分析 [J].介入放射学杂志,2018,27(04):366.
 ZHANG Jinxing,ZU Qingquan,SHI Haibin.Percutaneous metal stent implantation for the treatment of pancreatic cancer associated with obstructive jaundice: prognostic analysis of 42 patients[J].journal interventional radiology,2018,27(05):366.

备注/Memo

备注/Memo:
(收稿日期:2023- 06- 14)
(本文编辑:新 宇)
更新日期/Last Update: 2024-06-03